Fragment-based Drug Discovery: the Shape of Things to Come
Keyword(s):
To Come
◽
Fragment-Based Drug Discovery (FBDD) is here to stay. Validated as a technology with the delivery of Zelboraf (Vemurafenib) for the treatment of mutant B-RafV600E melanoma, it has become embedded within the pharmaceutical and biotechnology industries. FBDD has delivered clinical development candidates for a broad range of targets including some of the most challenging cases such as β-secretase (BACE1) and protein–protein interactions. But the best is surely still to come.
2018 ◽
pp. 135-176
2019 ◽
Vol 26
(21)
◽
pp. 3890-3910
◽
2020 ◽
Vol 27
(37)
◽
pp. 6306-6355
◽
2005 ◽
Vol 2
(3)
◽
pp. 179-207
◽
2020 ◽
Vol 20
(10)
◽
pp. 855-882
Keyword(s):